Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Golimumab - Janssen Biotech

Drug Profile

Golimumab - Janssen Biotech

Alternative Names: Anti-TNF-alpha monoclonal antibody - Centocor/Medarex; CNTO-148; MK-8259; SCH 900259; Shinponi; Simponi; Simponi Aria; Sympony; Symposony; Xinpini

Latest Information Update: 11 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centocor; Medarex
  • Developer Centocor; Centocor Ortho Biotech; Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Merck & Co; Mitsubishi Tanabe Pharma Corporation
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase I/II Hearing disorders
  • Phase I Type 1 diabetes mellitus
  • Discontinued Asthma; Cardiovascular disorders; Sarcoidosis; Uveitis

Most Recent Events

  • 10 Jul 2019 Janssen Biotech and Celsius Therapeutics sign a collaboration agreement to identify predictive biomarkers of response for VEGA trial
  • 12 Jun 2019 Additional efficacy results from GO-VIBRANT in Psoriatic arthritis presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
  • 12 Jun 2019 Pooled adverse events data from three phase III trials (GO-ALIVE, GO-VIBRANT and GO-FURTHER) in Ankylosing spondylitis, Psoriatic arthritis and Rheumatoid arthritis presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top